Prospectus | Jotup

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on:

Monday, April 1, 2024

Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points:

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

CH Auto Technology Corporation Ltd. Completes Business Combination

Retrieved on:

Sunday, March 31, 2024

Common stock, EV, Qiantu Motor, Growth, Cayman Islands, CFO, Acquisition, Sub, Business analyst, CSRC, Sister republic, Rights, MCAF, Mergers and acquisitions, Prospectus

Qun Lu, the founder and CEO of CHAFC, will continue to lead CH Auto, the parent company, as its Chairman, CEO and CFO after closing of the Business Combination.

Key Points:

Qun Lu, the founder and CEO of CHAFC, will continue to lead CH Auto, the parent company, as its Chairman, CEO and CFO after closing of the Business Combination.
Following the Business Combination, the securities of CH Auto, including its Class A ordinary shares, will not be listed for trading on any securities exchange.
In the event CH Auto completes the CSRC filing procedure, CH Auto plans to list its securities on The Nasdaq Stock Market.
However, as previously disclosed in the Prospectus, dated September 28, 2023, CHATC, MCAF, CH Auto and Merger Sub had the option to waive such conditions, and ultimately CHATC, MCAF, CH Auto and Merger Sub did waive those conditions to consummate the Business Combination.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on:

Sunday, March 31, 2024

Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points:

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SINTX Technologies Announces Proposed Public Offering of Common Stock

Retrieved on:

Friday, March 29, 2024

Form, Telephone, Sale, Attention, Prospectus, Form S-3

SALT LAKE CITY, UT, March 29, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering.

Key Points:

SALT LAKE CITY, UT, March 29, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering.
All shares of common stock in the offering are to be offered by SINTX.
SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes.
Maxim Group LLC is acting as sole placement agent, on a reasonable best efforts basis, for the proposed offering.

IB Acquisition Corp. Announces Closing of $115,000,000 Initial Public Offering, Including Full Exercise of Underwriter Over-Allotment Option

Retrieved on:

Thursday, March 28, 2024

Exercise, Sale, Security (finance), Prospectus, Suite, Bank

The units began trading on the Nasdaq Global Market under the symbol “IBACU” on March 26, 2024.

Key Points:

The units began trading on the Nasdaq Global Market under the symbol “IBACU” on March 26, 2024.
Each unit consists of one share of common stock and one right.
Each right entitles the holder to receive one-twentieth (1/20) of one share of common stock upon the consummation of an initial business combination.
ArentFox Schiff LLP acted as counsel to the Company and Ellenoff Grossman & Schole LLP acted as counsel to the underwriters.

Five Star Bancorp Announces Pricing of Common Stock Offering

Retrieved on:

Thursday, March 28, 2024

Five Star Bank, Growth, Communication, Form, Telephone, Keefe, Bruyette & Woods, Bank, Sale, Security (finance), Prospectus, Investment, S-3

RANCHO CORDOVA, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- (March 28, 2024) – Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the “Bank”), announced today the pricing of the previously announced underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $21.75 per share.

Key Points:

RANCHO CORDOVA, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- (March 28, 2024) – Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the “Bank”), announced today the pricing of the previously announced underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $21.75 per share.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 517,500 shares of Company common stock at the public offering price, less underwriting discounts and commissions.
Keefe, Bruyette & Woods, A Stifel Company is acting as the bookrunner for the offering.
The offering of common stock is being made pursuant to a registration statement on Form S-3 (File No.

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Retrieved on:

Thursday, March 28, 2024

Lewy body, Exercise, Patient, Research, Sale, Prospectus, Morgan Stanley, Unit, Series, Working capital, Dementia, CRVO, Security (finance)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders (the “Company”), today announced that it has entered into a definitive securities purchase agreement for a private placement to sell an aggregate of 2,532,285 units (the “Units”), each Unit comprised of (i) (A) one share of its common stock or (B) one pre-funded warrant to purchase shares of its common stock, and in each case, (ii) one Series A warrant to purchase shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement. A Unit comprised of one share of common stock and one Series A warrant shall have a purchase price of $19.745 and a Unit comprised of one pre-funded warrant and one Series A warrant shall have a purchase price of $19.744.

Key Points:

The pre-funded warrants have an exercise price of $0.001 per share, will be immediately exercisable and will not expire.
The private placement is expected to close on or about April 1, 2024, subject to customary closing conditions.
The financing is being led by RA Capital Management and includes participation from other new institutional investors, including Armistice Capital, Special Situations Funds and Soleus Capital.
Morgan Stanley and Canaccord Genuity are acting as placement agents for the private placement.

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Retrieved on:

Thursday, March 28, 2024

WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it has entered into a securities purchase agreement with certain existing accredited investors, including Bain Capital Life Sciences and Rock Springs Capital, to issue and sell an aggregate of 1,953,125 shares of Xilio common stock at a price of $0.64 per share and prefunded warrants to purchase up to an aggregate of 15,627,441 shares of Xilio common stock at a purchase price of $0.6399 per prefunded warrant share, through a private investment in public equity financing. The prefunded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full. Xilio anticipates receiving aggregate gross proceeds from the private placement of approximately $11.3 million, before deducting placement agent fees and expenses payable by the company. The private placement is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions. Xilio expects to use the proceeds from the private placement to fund working capital and other general corporate purposes.

Key Points:

Xilio anticipates receiving aggregate gross proceeds from the private placement of approximately $11.3 million, before deducting placement agent fees and expenses payable by the company.
The private placement is expected to close on April 2, 2024, subject to the satisfaction of customary closing conditions.
Xilio expects to use the proceeds from the private placement to fund working capital and other general corporate purposes.
Prior to the potential transition fee, Xilio is eligible to receive up to a total of $29.0 million in additional equity investments and a development milestone payment.

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Retrieved on:

Thursday, March 28, 2024

BofA Securities, Survival, Patient, SAN, Research, Sale, Prospectus, NRAS

Erasca anticipates the gross proceeds from the private placement will be approximately $45 million, before deducting placement agent fees and other offering expenses.

Key Points:

Erasca anticipates the gross proceeds from the private placement will be approximately $45 million, before deducting placement agent fees and other offering expenses.
The private placement is expected to close on or about April 2, 2024, subject to customary closing conditions.
The private placement was led by a high quality group of new and existing healthcare focused investors.
BofA Securities is acting as sole placement agent to Erasca in connection with the private placement.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, March 28, 2024

Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Plaque, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points:

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.